Clinical and Molecular Characterization of KRAS-Mutated Renal Cell Carcinoma
PRNRP represents a distinct <i>KRAS</i>-mutant RCC subtype with unique metabolic and genomic features linked to its distal nephron origin. This contrasts with the genomic complexity and aggressive clinical behavior observed in <i>KRAS</i>-mutant PRCC and URCC, highlighting the need for subtype-specific diagnostic criteria and therapeutic strategies.
Authors
- Ying‐Bei Chen (ORCID: https://orcid.org/0000-0001-5207-3648)
- Andrea López Sanmiguel (ORCID: https://orcid.org/0000-0002-8558-8194)
- Mark Dawidek (ORCID: https://orcid.org/0000-0003-2261-0857)
- Edward Tse
- Satish K. Tickoo (ORCID: https://orcid.org/0000-0002-9775-0478)
- Lina Posada Calderon
- Yash S. Khandwala (ORCID: https://orcid.org/0000-0001-9336-7407)
- Paul Russo (ORCID: https://orcid.org/0000-0002-6842-7815)
- Maria Isabel Carlo (ORCID: https://orcid.org/0000-0002-4786-7408)
- Jonathan Coleman (ORCID: https://orcid.org/0000-0002-6428-7835)
- Ed Reznik (ORCID: https://orcid.org/0000-0002-6511-5947)
- A. Ari Hakimi (ORCID: https://orcid.org/0000-0002-0930-8824)
- Victor E. Reuter
- Daniel Barbakoff (ORCID: https://orcid.org/0009-0002-6608-0245)
- Kuo Fengshen
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of British Columbia (CA)
- Cornell University (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-29
- DOI
- https://doi.org/10.3390/cancers17233832
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00